Nystagmus
Conditions
Interventions
Trade Name: N/A
Product Name: Memantine
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Capsule, hard
Route of administr
Sponsors
University Hospitals of Leicester NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with cingenital or acquired nystagmus over the age of 16 years. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients with contraindication for gabapentin or memantine such as epilepsy, renal impairment, pregnancy or breast-feeding. For women of childbearing potential, a pregnancy test will be performed and documentation of adequate contraception during the study drug administration will be obtained. Patients on medication incompatible with gabapentin or memantine, such as amantadin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): Completion of all examinations in 180 patients. A clinically significant improvement in visual acuity, (approximately >1 line logMAR scale), will be the primary endpoint. Secondary endpoint is a reduction of nystagmus and subjective improvement in visual acuity.;Secondary Objective: ;Main Objective: The main objective of the trial is to compare memantine and gabapentin treatment in nystagmus and to identify specific types and congenital and acquired nystagmus that respond to treatment with memantine or gabapentin in terms of improvement in visual acuity and reduction in the amount of nystagmus. | — |
Countries
United Kingdom
Outcome results
None listed